

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/5297962>

Functional and Structural Characterization of Four Glutaminases from *Escherichia coli* and *Bacillus subtilis* †

ARTICLE *in* BIOCHEMISTRY · JUNE 2008

Impact Factor: 3.02 · DOI: 10.1021/bi800097h · Source: PubMed

CITATIONS

38

READS

44

12 AUTHORS, INCLUDING:



Youngchang Kim

Argonne National Laboratory

96 PUBLICATIONS 5,007 CITATIONS

SEE PROFILE



Claudio Fabricio Gonzalez

University of Florida

41 PUBLICATIONS 849 CITATIONS

SEE PROFILE



Alex Savtchenko

Sanford Burnham Prebys Medical Discovery I...

157 PUBLICATIONS 4,147 CITATIONS

SEE PROFILE



Alexander F Yakunin

University of Toronto

119 PUBLICATIONS 2,813 CITATIONS

SEE PROFILE

Published in final edited form as:

Biochemistry. 2008 May 27; 47(21): 5724–5735. doi:10.1021/bi800097h.

Functional and Structural Characterization of Four Glutaminases from *Escherichia coli* and *Bacillus subtilis*[†]

Greg Brown[‡], Alex Singer[‡], Michael Proudfoot[‡], Tatiana Skarina[‡], Youngchang Kim[§], Changsoo Chang[§], Irina Dementieva[§], Ekaterina Kuznetsova[‡], Claudio F. Gonzalez^{||}, Andrzej Joachimiak[§], Alexei Savchenko[‡], and Alexander F. Yakunin^{‡,*}

[‡]Banting and Best Department of Medical Research, Ontario Centre for Structural Proteomics, UniVersity of Toronto, Toronto, Ontario M5G 1L6, Canada

[§]Midwest Center for Structural Genomics and Structural Biology Center, Biosciences DiVision, Argonne National Laboratory, Argonne, Illinois 60439

^{||} Department of Microbiology and Cell Science, UniVersity of Florida, Gainesville, Florida 32611-0700

Abstract

Glutaminases belong to the large superfamily of serine-dependent β -lactamases and penicillin-binding proteins, and they catalyze the hydrolytic deamidation of L-glutamine to L-glutamate. In this work, we purified and biochemically characterized four predicted glutaminases from *Escherichia coli* (YbaS and YneH) and *Bacillus subtilis* (YlaM and YbgJ). The proteins demonstrated strict specificity to L-glutamine and did not hydrolyze D-glutamine or L-asparagine. In each organism, one glutaminase showed higher affinity to glutamine (*E. coli* YbaS and *B. subtilis* YlaM; K_m 7.3 and 7.6 mM, respectively) than the second glutaminase (*E. coli* YneH and *B. subtilis* YbgJ; K_m 27.6 and 30.6 mM, respectively). The crystal structures of the *E. coli* YbaS and the *B. subtilis* YbgJ revealed the presence of a classical β -lactamase-like fold and conservation of several key catalytic residues of β -lactamases (Ser74, Lys77, Asn126, Lys268, and Ser269 in YbgJ). Alanine replacement mutagenesis demonstrated that most of the conserved residues located in the putative glutaminase catalytic site are essential for activity. The crystal structure of the YbgJ complex with the glutaminase inhibitor 6-diazo-5-oxo-L-norleucine revealed the presence of a covalent bond between the inhibitor and the hydroxyl oxygen of Ser74, providing evidence that Ser74 is the primary catalytic nucleophile and that the glutaminase reaction proceeds through formation of an enzyme–glutamyl intermediate. Growth experiments with the *E. coli* glutaminase deletion strains revealed that YneH is involved in the assimilation of L-glutamine as a sole source of carbon and nitrogen and suggested that both glutaminases (YbaS and YneH) also contribute to acid resistance in *E. coli*.

Glutaminases (EC 3.5.1.2) are present in most bacteria and eukaryotes and catalyze the hydrolytic deamidation of L-glutamine to L-glutamate and free NH_4^+ (1). These enzymes are strictly specific to L-glutamine and differ from glutaminase–asparaginases (EC 3.5.1.1), which

[†]This work was supported by grants from Genome Canada (through the Ontario Genomics Institute), the National Institutes of Health (Grant GM074942), and the Department of Energy, Office of Biological and Environmental Research (under Contract DE-AC02-06CH11357).

© 2008 American Chemical Society

*Corresponding author. Phone: (416) 978-4013. Fax: (416) 978-8528. E-mail: a.iakounine@utoronto.ca.

SUPPORTING INFORMATION AVAILABLE

Three figures showing the effect of pH, divalent metal cations, phosphate, and β -lactam antibiotics on glutaminase activity of YbaS and YbgJ, as well as one table with complete MAD data collection statistics for YbaS and YbgJ. This material is available free of charge via the Internet at <http://pubs.acs.org>.

deamidate both asparagine and glutamine. Poorly characterized glutaminases belong to the large group of serine β -lactamases and penicillin-binding proteins, which have a common evolutionary origin and share the protein fold, structural motifs, and catalytic mechanism (2). This large group of enzymes includes DD-peptidases, transpeptidases, glutaminases, and three classes of well-characterized serine β -lactamases (A, C, and D) (3). β -Lactamases (EC 3.5.2.6) catalyze the hydrolysis of an amide bond (N–CO) in the β -lactam ring of antibiotics of the penicillin/cephalosporin family constituting the most common mechanism of bacterial resistance to β -lactam antibiotics, whereas penicillin-binding proteins have transpeptidase, transglycosylase, and carboxypeptidase activities and are involved in the biosynthesis of the bacterial cell wall (2,4,5). The representatives of all β -lactamase and DD-peptidase families have been characterized both structurally and biochemically, and the molecular mechanisms of the catalysis have been established (6–9).

In microorganisms, glutaminases have been reported from many species including Gram-positive and Gram-negative bacteria, yeasts, and fungi (1,10). Several microbial enzymes (from *Micrococcus luteus*, *Rhizobium etli*, *Bacillus pasteurii*, and *Lactobacillus rhamnosus*) were purified and partially characterized (11–14). All of these enzymes (except for the *L. rhamnosus* glutaminase) were found to be soluble proteins, and they all showed low affinity to glutamine (K_m from 1.5 to 9.5 mM). The recently solved crystal structure of a major fragment of the *M. luteus* glutaminase (PDB 2dfw) revealed the presence of a putative catalytic site in the N-terminal domain (15). Mutational analysis of this protein indicated that Ser64, Lys67, and Glu160 are essential for catalysis and suggested that the catalytic mechanism might be similar to that of the class A β -lactamases (16). Many organisms including mammals produce two glutaminases, which share 30–40% sequence identity (17–20). In *Escherichia coli*, the presence of two glutaminases (A and B) was experimentally demonstrated over 30 years ago (21,22). Glutaminase A seems to be the main isoenzyme, and it was purified in apparently homogeneous form (21). Glutaminase B comprised a minute fraction of total cellular protein, and after 6000-fold purification, the purified preparation contained only about 40% of this enzyme (22). Studies on the regulation of the cellular levels of two glutaminases have revealed that glutaminase A levels are stimulated by high NH_4^+ and inhibited by cAMP, while glutaminase B levels were independent of the growth conditions (23–25). In the *E. coli* genome, as well as in the genome of the Gram-positive bacterium *Bacillus subtilis*, there are two genes encoding putative glutaminases, but only for the *B. subtilis* YbgJ has the bioinformatic prediction been recently confirmed experimentally (26). The expression of this glutaminase has been shown to be stimulated in response to glutamine in the culture medium, suggesting that this protein is involved in glutamine assimilation (26). However, the physiological functions of the other glutaminases remain unknown.

In this work, we present the results of biochemical characterization of the four predicted glutaminases from *E. coli* (YbaS and YneH) and *B. subtilis* (YbgJ and YlaM). We determined the crystal structures of YbaS and YbgJ in a free state, as well as the structure of the covalent complex of YbgJ with the glutaminase inhibitor 6-diazo-5-oxo-L-nor-leucine (DON)¹. Growth experiments with the *E. coli* glutaminase deletion strains suggest that YneH is involved in the assimilation of glutamine and that both YneH and YbaS also contribute to acid resistance in this organism.

¹Abbreviations: DON, 6-diazo-5-oxo-L-norleucine; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; MAD, multiple-wave-length anomalous diffraction; MES, 2-(N-morpholino)ethanesulfonic acid; ON, 5-oxo-L-norleucine; SAD, single anomalous diffraction; SDS–PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis.

EXPERIMENTAL PROCEDURES

Gene Cloning and Protein Purification

Genes (*ybaS* and *yneH* from *E. coli* and *ylaM* and *ybgJ* from *B. subtilis*) were PCR-amplified using chromosomal DNA of the *E. coli* W3110 strain and the *B. subtilis* 168 (ATCC 23857D-5). The restriction sites *Bam*HI and *Nde*I were added to the PCR primers and used to directionally clone the PCR product into the modified pET15b (Novagen) as previously described (27). The recombinant plasmid was transformed into the *E. coli* BL21(DE3) strain for overexpression. Expression and purification of His₆-tagged proteins were described previously (28,29). All four proteins were well expressed and purified with high yield (2–5 mg/L of culture) and purity (over 95% as verified by SDS–PAGE gels and Coomassie staining). Purified proteins were stored at –80 °C, except for YbaS, which was unstable and was stored in liquid nitrogen.

Gel filtration analysis of the oligomeric state of glutaminases was performed with a Superose 12 10/300 GL column (Amersham Biosciences) equilibrated with 10 mM HEPES-K (pH 7.5) and 0.2 M NaCl using AKTA FPLC (Amersham Biosciences). Protein standards included aldolase (158 kDa), albumin (67 kDa), ovalbumin (43 kDa), chymotrypsinogen (25 kDa), and ribonuclease A (13.7 kDa).

Site-Directed Mutagenesis of YbaS

Site-directed mutagenesis of YbaS was performed using a protocol based on the QuikChange site-directed mutagenesis kit from Stratagene.

DNA encoding wild-type YbaS cloned into the modified pET15b was used as a template for mutagenesis. Plasmid was purified from the resulting colonies using the Qiaprep Spin Mini Prep kit (Qiagen), and all mutations were verified by DNA sequencing. Verified plasmids containing the desired mutations were transformed into the *E. coli* BL21(DE3) strain, and the mutant YbaS proteins were overexpressed and purified in the same manner as the wild-type YbaS.

Enzymatic Assays

Glutaminase activity was analyzed using two assays: by measurement of NH₄⁺ production by the continuous assay with glutamate dehydrogenase (30) or by the chromogenic assay with L-glutamyl-*p*-nitroanilide. The reaction mixture for the continuous glutaminase assay contained (in a final volume of 1 mL) 50 mM HEPES-K buffer (pH 7.5, or pH 8.0 for YbgJ), 50 mM L-glutamine, 0.2 mM NADH, 1 mM EDTA, 0.2 mM α-ketoglutarate, 1 unit of glutamate dehydrogenase (Sigma), and 0.1–0.2 μg of glutaminase. The oxidation of NADH was followed continuously at 340 nm. Metal effects were determined using a 10 min end-point assay. pH profiles were determined using a buffer system described by Heering et al. (31). Alternatively, glutaminase activity of purified proteins was measured using the chromogenic substrate L-glutamyl-*p*-nitroanilide (Sigma) in a reaction mixture containing 50 mM HEPES-K buffer (pH 7.5) and 10 mM L-glutamyl-*p*-nitroanilide (final volume 1 mL). The activity was followed at 410 nm. For *K_m* and *V_{max}* determination, the glutaminase assays contained 0.1 – 150 mM L-glutamine. Kinetic parameters were determined by nonlinear curve fitting from the Lineweaver–Burk plot using the GraphPad Prism software (version 4.00 for Windows; GraphPad Software, San Diego, CA). For sigmoidal curve fitting, this program uses the equation $V = (V_{\max} S^h) / (K_{0.5}^h + S^h)$.

β-Lactamase activity of glutaminases with nitrocefin as a substrate was assayed essentially as previously described (32). Reaction mixtures (1 mL) contained 50 mM sodium phosphate buffer (pH 7.4), 50 μM nitrocefin (dissolved in DMSO), and 5–20 μg of protein. After 20 min

incubation at 37 °C, the increase in absorbance at 486 nm was measured ($\epsilon = 20.5 \text{ mM}^{-1} \text{ cm}^{-1}$).

Construction of the *E. coli* Glutaminase Deletion Strains and Growth Experiments

The *E. coli* *AybaS* and *AyneH* deletion mutants were obtained from the Keio collection of *E. coli* deletion mutants (33). The kanamycin-resistance cassette was excised from the chromosome using the procedure described by Datsenko and Wanner (34). The double glutaminase deletion mutant (*AybaS*,*AyneH*) was prepared using reciprocal P1 transduction as described previously (35). The deletions of glutaminase genes were individually validated by colony PCR using specific primers complementary to the upstream and downstream regions of each glutaminase gene. Growth experiments with the *E. coli* wild-type (BW25113) and glutaminase deletion (*AybaS*, *AyneH*, and *AybaS*,*AyneH*) strains were performed essentially as previously described (36) using LB medium with various pHs (4.0, 4.5, 5.0, 5.5, 6.0, 6.5, and 7.0; adjusted after autoclaving) or minimal medium M9 containing 20 mM L-glutamine as a sole source of carbon and nitrogen (pH 7.0) or M9 medium containing 20 mM MES-K buffer (pH 4.5, 5.0, 5.5, or 6.0), 0.4% glucose, and 20 mM L-glutamine.

Protein Crystallization and Data Collection

Crystals of YbaS and YbgJ were grown at 21 °C by the hanging drop vapor diffusion method with 2 μL of protein sample mixed with an equal volume of the reservoir buffer as previously described (37). The crystals of YbaS grew after 3–5 days in the presence of 25% polyethylene glycol 3350, 0.2 M MgCl_2 , and 0.1 M HEPES-Na (pH 7.5). The YbgJ crystals were grown in 30% polyethylene glycol 1500, 0.2 M NaCl, 5% glycerol, 0.1 mM DTT, and 0.1 M HEPES-Na (pH 7.5), whereas the crystals of the YbgJ + DON complex were grown in 14.5% polyethylene glycol 1500, 0.5 M NaCl, 12% glycerol, 0.1 M HEPES-Na (pH 7.5), and 10 mM DON. For diffraction studies, the crystals were stabilized with the crystallization buffer supplemented with 20% ethylene glycol as a cryoprotectant and flash frozen in liquid nitrogen.

Structure Determination

All diffraction data were collected on the 19-ID beamline of the Structural Biology Center at the Advanced Photon Source (38). YbaS was crystallized in two forms, both tetragonal (space group *I*4) and orthorhombic (space group *P*2₁2₁2₁). A MAD data set was collected for the tetragonal crystal (wavelengths of 0.97948, 0.97962, and 0.95667 Å), and a single wavelength (0.97978 Å) was collected on the orthorhombic crystal. Phases were obtained, and an initial model was built from the tetragonal data set using HKL3000 (39), but when it was realized that the orthorhombic crystal diffracted to higher resolution, the initial model from the tetragonal data set was used to obtain phases for the orthorhombic crystal by molecular replacement using AMORE (40). Subsequent model building using COOT (41) and refinement using REFMAC 5.1 (42) and TLS (43) were then performed. ARP/wARP (44) was used to generate the initial solvent model, while manual water picking was used to add additional waters. All possible waters with nearest neighbor distances to other atoms of <2.3 Å or >4.5 Å or had overly high *B*-factors (>80 Å²) or low electron densities (<1.0 σ) were manually omitted. The final model (*R*_{work} of 14.5% and *R*_{free} of 17.8%) contains 10487 atoms with 4 molecules in the asymmetric unit, and each molecule of the asymmetric unit contains 309 out of 310 residues of YbaS.

For YbgJ, MAD data collection at wavelengths of 0.97910, 0.97921, and 0.954 Å was used to obtain phase information. Initial phases, initial solvent flattening, and an initial model were obtained using SOLVE/RESOLVE (45), and manual building from this initial model using COOT (41) followed by refinement using REFMAC5 (42) was used to complete the structure. Solvent molecules were added and then pruned as described for YbaS. The final model was refined to 2.0 Å resolution (with an *R*_{cryst} of 21.6% and an *R*_{free} of 24.5%) and contains 5195

atoms including 2 molecules in the asymmetric unit, with 312 out of 327 residues of YbgJ present in each molecule of the asymmetric unit. Residues 6–12 and 36–44 of YbgJ were disordered and could not be built in the electron density map.

The structure of YbgJ plus DON was determined using SAD. Initial phases, solvent flattening, and automatic model building were performed using HKL3000 (39), with subsequent manual model building using COOT (41) and refinement using REFMAC 5.2 (42). Solvent was initially added using ARP/wARP (44), with subsequent automatic and manual water picking using COOT. Throughout refinement, picked water molecules were pruned using similar criteria as described above. However, prior to adding solvent, a long unmodeled tube of electron density originating from the hydroxyl group of Ser74 was observed (see Figure 6) and ascribed to covalently bound inhibitor. This covalently bound inhibitor fits optimally as 5-oxo-L-norleucine; a covalent bond between it and the hydroxyl group of Ser74 was made first by placing the relevant atoms within covalent-bonding distance and then using CCP4i within the CCP4 program suite (46) to form the linkage. The final model (resolution of 2.3 Å, R_{cryst} of 20.0%, and R_{free} of 25.2%) contains 5032 atoms with 2 molecules in the asymmetric unit. Electron density corresponding to residues 102–117 is not seen, and density around residues 8–12 and 283–286 is poor. Data collection and refinement statistics are shown in an abbreviated form in Table 2 (and in Supporting Information Table 1), which presents data collection statistics for the peak wavelength of MAD data sets. The coordinates have been deposited in the Protein Data Bank under accession codes 1u60 (YbaS), 1mki (YbgJ), and 3brm (YbgJ + DON complex).

RESULTS AND DISCUSSION

Sequence Analysis of Glutaminases

Glutaminases are widely distributed in bacteria and eukaryotes but seem to be absent in archaea, thermophiles, and plants (1). Many sequenced genomes contain two genes encoding predicted glutaminases of the β -lactamase superfamily. The *E. coli* genome encodes two predicted glutaminases, YbaS (P77454, GluA1, 310 amino acids) and YneH (P0A6W0, GluA2, 308 amino acids), which share 38% sequence identity. The YbaS gene is located upstream and cotranscribed with *ybaT* encoding an uncharacterized amino acid transporter (APC superfamily), whereas the YneH gene seems to comprise a single gene operon (EcoCyc database, <http://www.ecocyc.org/>). Likewise, the *B. subtilis* genome has two genes encoding predicted glutaminases, YbgJ (O31465, GluA1, 327 amino acids) and YlaM (O07637, GluA2, 309 amino acids) with 44% sequence identity to each other and 33–38% sequence identity to predicted *E. coli* glutaminases. The presence of glutaminase activity in YbgJ was recently reported (26). The *B. subtilis* *ybgJ* is located upstream and cotranscribed with a gene encoding the glutamine transporter YbgH (26). Sequence alignment of the predicted glutaminases from *E. coli* and *B. subtilis* with the sequences of several known glutaminases revealed the presence of over 40 absolutely conserved residues including the predicted β -lactamase motif 1 (2), a catalytic diad Ser-X-X-Lys (Ser66-X-X-Lys69 in YbaS) (Figure 1). The β -lactamase sequence motif 3 (Lys/Arg-Ser/Thr-Gly) (2) was also recognizable in glutaminases (Lys259-Ser260-Gly261 in YbaS), whereas only Ser (Ser160 in YbaS) could be identified for the Ser-Asp-Asn triad of the class A β -lactamase motif 2 (Figure 1). The class C β -lactamases contain a conserved Tyr residue (Tyr150 in AmpC from *Enterobacter cloacae*) instead of Ser in motif 2 (2), which also has no obvious counterpart in the glutaminase sequences. Thus, sequence analysis indicates that glutaminases retained motifs 1 and 3 of β -lactamases but differ in motif 2.

Protein Purification and Oligomeric State

Genes encoding the four predicted glutaminases from *E. coli* (YbaS and YneH) and *B. subtilis* (YbgJ and YlaM) were overexpressed in *E. coli*, and the recombinant proteins were affinity purified (see Experimental Procedures for details). All four proteins were expressed in soluble form, and a one-step purification using metal-chelate affinity chromatography on a Ni^{2+} -NTA affinity resin produced glutaminase preparations with over 95% homogeneity as assessed by SDS-PAGE gels (not shown). Gel filtration analysis (data not shown) of the oligomeric state of purified proteins revealed that both YbaS (32.9 kDa) and YbgJ (36.2 kDa) were tetramers in solution (148.8 and 138.1 kDa, respectively), whereas YneH (33.5 kDa) and YlaM (34.0 kDa) were dimers (74.9 and 72.6 kDa, respectively).

Enzymatic Studies

All purified proteins exhibited glutaminase activity when assayed in an enzyme-coupled assay with glutamate dehydrogenase, which detects the formation of free NH_4^+ . Glutaminase activity of YbgJ was also confirmed using the chromogenic substrate glutamate-*p*-nitroanilide, but the rate of hydrolysis of this substrate [$0.3 \mu\text{mol min}^{-1} (\text{mg of protein})^{-1}$] was 400–450 times lower than that of L-glutamine. With L-glutamine as a substrate, all glutaminases expressed maximal activity at pH 7.5–8.0 (Supporting Information Figure 1). However, the glutaminase activity of YbaS was more resistant to low pH than in other glutaminases, and this enzyme exhibited significant activity even at pH 4.5 (Supporting Information Figure 1A). On the basis of the pH profiles of glutaminase activity, we propose that the *E. coli* YbaS and YneH correspond to glutaminases A and B, respectively, that were identified in this organism over 30 years ago (21,22,47).

All glutaminases were highly specific to L-glutamine as a substrate and showed no activity against L-asparagine or D-glutamine. With L-glutamine, all four glutaminases demonstrated a sigmoidal saturation curve, with a Hill coefficient $n_H = 1.8$ –2.8 indicating positive cooperativity in glutamine binding. This observation is consistent with the oligomeric state of glutaminases in solution (dimers and tetramers). The *E. coli* YbaS and *B. subtilis* YlaM exhibited higher affinity to glutamine (K_m 7.3 and 7.6 mM, respectively) than the *E. coli* YneH and *B. subtilis* YbgJ (K_m 30.6 and 27.6 mM, respectively) (Table 1). Biochemically characterized glutaminases from various organisms show a broad range of K_m for L-glutamine (0.1–21.0 mM) and k_{cat}/K_m values (6.1×10^3 to $11.6 \times 10^5 \text{ M}^{-1} \text{ s}^{-1}$) (BRENDA database; <http://www.brenda-enzymes.org/>). Therefore, the glutaminases from *E. coli* and *B. subtilis* have kinetic parameters similar to those of other glutaminases. Thus, glutaminases exhibit low affinity to L-glutamine (high K_m), but at the same time they are highly selective for this substrate and show no activity against D-glutamine or L-asparagine. Low substrate affinity and high substrate selectivity were also observed in glutamine synthetases (EC 6.3.1.2; K_m for glutamate up to 50 mM), glucokinases (EC 2.7.1.2; K_m for glucose up to 24 mM), and high- K_m phosphodiesterases (EC 3.1.4.17; K_m up to 3 mM) (BRENDA database; <http://www.brenda-enzymes.org/>).

In contrast to the salt-tolerant glutaminase from *M. luteus* (13), the rate of glutamine hydrolysis by the *E. coli* YbaS was not stimulated by NaCl (up to 0.2 M) and dropped two times in the presence of 0.5 M NaCl (not shown). Moreover, on the contrary to the phosphate-activated glutaminases from mammals and *B. pasteurii* (12,17), the activity of the *E. coli* YbaS and YneH was inhibited by low concentrations of PO_4^{3-} ($\text{IC}_{50} = 17.2$ –17.4 mM) (Supporting Information Figure 2). All four glutaminases were also inhibited by low concentrations of divalent metal cations, Mg^{2+} and Mn^{2+} (Supporting Information Figure 1). YbaS was ~10 times more sensitive to these cations (IC_{50} for $\text{Mg}^{2+} = 0.2$ mM and IC_{50} for $\text{Mn}^{2+} = 0.1$ mM) than the other three glutaminases ($\text{IC}_{50} = 1.7$ –5.5 mM for Mg^{2+} and 0.7–1.3 mM for Mn^{2+}).

The glutamine analogue 6-diazo-5-oxo-L-norleucine (DON) has been shown to bind and irreversibly inactivate glutaminase-asparaginases from several organisms at low concentrations (60–100 μM) (48,49). Crystal structures of three glutaminase-asparaginases complexed with DON demonstrated that this inhibitor becomes covalently attached to the catalytic threonine residue in these enzymes (49–51). Whereas glutaminases from the β -lactamase superfamily were also shown to be inhibited by DON, these enzymes exhibited much lower sensitivity to this inhibitor (21). Our work with highly purified glutaminases revealed that even high concentrations of DON (2–10 mM) produced incomplete (45–90%) inhibition of glutaminase activity of YbaS or YbgJ, suggesting that they employ a catalytic mechanism different from that of glutaminase-asparaginases.

Highly purified preparations of the *E. coli* YbaS showed low, but detectable β -lactamase activity [$24.4\text{--}30.5\text{ nmol min}^{-1}(\text{mg of protein})^{-1}$] against nitrocefin, a general β -lactamase substrate (52). This activity could not be eliminated by additional purification steps (by gel filtration or using the second Ni column after the cleavage of the His tag) but was not detectable in the catalytically inactive YbaS mutants (K69A, S160A, K259A). In addition, glutaminase activity of YbaS was inhibited by the β -lactam antibiotics penicillin ($K^i = 6.4\text{ mM}$) or ampicillin ($K^i = 3.5\text{ mM}$) (Supporting Information Figure 3A). Kinetic analysis of the YbaS glutaminase activity in the presence of ampicillin demonstrated that this antibiotic acted as a competitive inhibitor of glutamine hydrolysis (Supporting Information Figure 3B) and induced an increase in K_m for glutamine without affecting its k_{cat} (Table 1). As well, the commercial preparation of the *E. cloacae* penicillinase (a class C β -lactamase) exhibited low, but detectable glutaminase activity [$20.7 \pm 3.4\text{ nmol min}^{-1}(\text{mg of protein})^{-1}$]. Thus, the obtained results indicate that YbaS retained a low level of β -lactamase activity and the β -lactamase substrates are apparently capable of binding to the glutamine binding site and acting as competitive inhibitors of glutamine hydrolysis by glutaminases.

Crystal Structures of YbaS and YbgJ

Crystal structures of unliganded YbaS (1u60) and YbgJ (1mki) were determined by MAD phasing and revealed a tetrameric protein arranged as a dimer of dimers with each subunit providing two α -helices ($\alpha 6$ and $\alpha 10$ in YbaS and $\alpha 5$ and $\alpha 9$ in YbgJ) for the dimer/dimer contact (Figure 2A,B). The monomers of both proteins have two compact domains: an α/β -sandwich tightly associated with a mostly α -helical domain. In the YbaS structure, five β -strands ($\beta 1$, $\beta 2$, $\beta 8$, $\beta 9$, and $\beta 10$) make an antiparallel β -sheet flanked by four α -helices ($\alpha 1$, $\alpha 15$, $\alpha 16$, and $\alpha 17$) on the protein surface side and by the α -helix 12 on the opposite face (Figure 2C). YbgJ has a very similar structure, but its β -sheet contains six β -strands (Figure 2D). The recently solved crystal structure of a major fragment of the *M. luteus* K3 glutaminase revealed the presence of a C-terminal extension (141 amino acids) (15) representing a poorly characterized STAS domain (PROSITE entry PS50801).

The search for structural homologues of YbaS using the DALI (53) (<http://www.ebi.ac.uk/dali>) and SSM (<http://www.ebi.ac.uk/msd-srv/ssm>) databases identified the *B. subtilis* YbgJ (1mki, this work), the *M. luteus* glutaminase (2dfw), and the putative glutaminase GlsA from *Geobacillus kaustophilus* (2pby) as the closest structural homologues (Z-score 10.9–12.3, rmsd 1.5–1.6 Å). These analyses also recognized a group of homologous structures of several β -lactamases and penicillin-binding proteins with lower structural similarity and Z-scores ranging from 3.8 to 5.8 (rmsd 2.3–2.8 Å; PDB codes 2c5w, 2bg4, 2bg3, 2bg1, 2c6w, 2fff). All of these proteins have low sequence similarity to glutaminases (less than 25% sequence identity).

Putative Active Site

Crystal structures of YbaS and YbgJ revealed the presence of a deep cleft, whose walls are formed by the β -sheet and several α -helices of the helical domain ($\alpha 3$, $\alpha 6$, and $\alpha 8$) (Figure 2C,D). The YbgJ Ser74 (Ser66 in YbaS), which occurs within the β -lactamase motif 1 (Ser-X-X-Lys), is located at the bottom of this cleft and is likely to function as a catalytic nucleophile in the glutaminase reaction (Figure 3). As in the *E. coli* RTEM-1 β -lactamase (6), this Ser is surrounded by the side chains of three conserved residues located on the equivalent secondary structural elements: Lys77, Lys268, and Ser269 in YbgJ (Lys69, Lys259, and Ser260 in YbaS) (Figure 3). Lys77 is hydrogen bonded (2.8 Å) to the side chain of the conserved Asn126 (Asn117 in YbaS), which is equivalent to the RTEM-1 Asn132 (Figure 3). The YbgJ Asn126 (Asn117 in YbaS) is close to the conserved Asn177 (Asn168 in YbaS). Another YbgJ residue, Gly270 (Gly261 in YbaS), is conserved and located on the $\beta 7$ strand in both β -lactamases and glutaminases. The absence of the side chain at this position is perhaps essential for the catalytic reaction of β -lactamases and glutaminases. The structure of YbgJ showed an additional small electron density close to the predicted catalytic nucleophile Ser74 which was interpreted as a covalently bound phosphate in the PDB submission (1mki). However, this density was not present in the structures of the YbgJ–DON complex or YbaS, and the mass spectrometric analysis of purified YbgJ produced no evidence for the presence of any covalent modification in this protein. Therefore, this additional density might actually represent a noncovalently associated solvent molecule.

In contrast to β -lactamases, the active site of glutaminases accommodates the bulky side chains of three conserved tyrosine residues: Tyr37, Tyr201, and Tyr253 in YbgJ and Tyr29, Tyr192, and Tyr244 in YbaS. This is consistent with the smaller size of the glutaminase substrate. The YbgJ Tyr253 (Tyr244 in YbaS) occupies the position equivalent to that of the conserved Ser130 of the *E. coli* RTEM-1 β -lactamase (Figure 3). The latter residue is positioned close to the catalytic Ser70 and is involved in the proton transfer from Lys73 to the nitrogen atom of the substrate (6). In the class C β -lactamase from *E. cloacae* (AmpC), Tyr150 exists in the position occupied by Ser130 in class A enzymes (54) (Figure 4). In YbgJ, the side chain hydroxyl oxygen of Tyr253 is 3.0 Å away from the putative nucleophile Ser74 and 3.2 Å away from the side chain of conserved Lys77, which is homologous to Lys73 of RTEM-1 (Figure 4). While Tyr253 of YbgJ and Tyr150 of AmpC are not similar in orientation and located in different secondary structure elements, their oxygen atoms are only 2.14 Å apart (Figure 4), suggesting that they are functionally equivalent. Therefore, Tyr253 is likely involved in the proton relay pathway in YbgJ. Tyr201 is placed in another corner of the YbgJ catalytic cleft (4.8 Å from Ser74) and occupies the position equivalent to that of the RTEM-1 Glu166 (Asn166 is shown because the E166N mutant protein was used for crystallization) (6) (Figure 4). In class A β -lactamases, Glu166 functions as the general base of the deacylation step and coordinates the nucleophilic water molecule (6). Hence, Tyr201 might have the same role in the glutaminase reaction.

Mutational Studies of YbaS

The putative catalytic cleft of glutaminases accommodates over a dozen residues absolutely conserved in these enzymes. To check the role of these residues in catalysis, we performed alanine replacement mutagenesis of YbaS using specifically designed PCR primers. Analysis of glutaminase activity of mutant proteins revealed that most mutations resulted in proteins with greatly reduced activity (Figure 5). S260A and Y29A had 16.5% and 32.5% of the wild-type activity, respectively, whereas all other mutants retained only 0.8–5.6% of activity. The G261A mutant retained 54.7% of activity (V_{\max}), but its affinity to glutamine dropped 3.2 times (K_m increased to 23.7 mM) (Table 1). This indicates that the introduction of even the small Ala side chain to the position of the conserved Gly261 affects mainly the binding of glutamine to the enzyme active site. Glu162 is not conserved in glutaminases, and the YbaS E162A mutant

showed the wild-type level of activity and substrate affinity (Figure 5 and Table 1). Thus, the putative catalytic cleft described above and conserved residues are likely to represent the glutaminase active site.

Structure of the YbgJ–DON Complex and Substrate Binding in Glutaminases

YbgJ was also crystallized in the presence of the glutaminase inhibitor DON, and the structure of the YbgJ–DON complex was solved independently of the apo-YbgJ structure using SAD phasing to a resolution of 2.3 Å (3brm) (Figure 3B and Figure 6). The structure revealed continuous electron density connecting the inhibitor to the side chain of Ser74 (Ser66 in YbaS), indicating the presence of a covalent bond between these moieties (1.3 Å). Previous studies with the *Pseudomonas* 7A glutaminase–asparaginase demonstrated that this enzyme removes the diazo group of DON, releasing N₂ and forming two covalent bonds between the inhibitor C5 (Cδ) and the hydroxyl oxygens of Thr20 and Tyr34 (50). In the structure of the YbgJ–DON complex, the Tyr253 side chain hydroxyl oxygen is positioned quite close to the inhibitor C6 (Cε) atom (2.2 Å), but the structure only shows the covalent bond between this atom and the Ser74 hydroxyl oxygen (1.3 Å) (Figure 3B and Figure 6). The formation of this covalent enzyme–inhibitor complex was previously predicted for deamidases but was never observed experimentally (50). It appears that YbgJ removes the diazo group of DON, producing N₂ and 5-oxo-L-norleucine (ON) covalently bound to the Ser74 side chain through its terminal (C6) carbon atom. In the crystallization solution, this linkage cannot be further processed and thus produces a stable acylenzyme intermediate.

The YbgJ–DON (actually YbgJ–ON) complex is further stabilized by interactions between the C5 (Cδ) carbonyl oxygen of the inhibitor and the main chain NH groups of Ser74 (3.1 Å) and Val271 (2.6 Å) (oxyanion hole) (Figure 3B). The α-carboxyl oxygens of ON are coordinated by interactions with the side chains of Asn126 (3.0 Å) and Tyr201 (2.6 Å), whereas its α-amido group interacts with the side chains of Gln73 (2.8 Å) and Glu170 (2.8 Å).

Thus, we propose that the side chain O^{ε1} and N^{ε1} of L-glutamine bind to the YbgJ active site near the catalytic nucleophile Ser74 (Ser66 in YbaS) (Figure 7). The side chain δ-carbonyl oxygen of glutamine might be coordinated by the oxyanion hole formed by the main chain NH groups of Ser74 and Val271 (Ser66 and Val262 in YbaS). The side chain of Tyr253 (Tyr244 in YbaS), which is close to Ser74 (2.6 Å), is likely to be hydrogen bonded to the glutamine N^{ε2} (the leaving group) (Figure 7). The α-amino group of glutamine is predicted to be coordinated by hydrogen bonds with the side chains of Tyr37, Gln73, and Glu170 (Tyr29, Glu65, and Glu161 in YbaS), whereas the glutamine α-carboxyl oxygens are likely to be hydrogen bonded with the side chains of Asn126 and Asn177 of YbgJ (Asn117 and Asn168 in YbaS) (Figure 7).

Implications for the Potential Catalytic Mechanism of Glutaminases

The conservation of overall β-lactamase structure and several β-lactamase catalytic residues in glutaminases, as well as the presence of low β-lactamase activity in YbaS, suggests that glutaminases use a β-lactamase-like catalytic mechanism for the deamidation of glutamine. The proposed model of the glutaminase catalytic mechanism is based on the mechanism of the *E. coli* RTEM-1 β-lactamase described by Strynadka et al. (6) and proposes the formation of a glutamyl-enzyme covalent intermediate at the Ser74 O^γ acting as a catalytic nucleophile (Figure 8). The important role of this residue in glutaminase catalysis is supported by the very low activity of the YbaS S66A mutant protein (Figure 5). Lys77 is likely to assist in the nucleophilic attack by acting as a general base, thereby accepting the proton from the Ser74 O^γ and transferring it to the Tyr253 side chain oxygen. This results in the tetrahedral intermediate-1 (Figure 8). The polarization of the hydrolyzable C–N bond of glutamine is enhanced by the hydrogen bonds from the oxyanion hole (the main chain NH groups of Ser74

and Val271) to the carbonyl oxygen atom O^{ε1}. The formation of a glutamyl-enzyme intermediate is induced by the proton transfer from Tyr253 to the substrate N^{ε2} (the leaving group) and accompanied by the release of ammonia, the first reaction product (Figure 8). Similar to β-lactamases, the deacylation of a glutamyl-enzyme intermediate is likely accomplished by a general base-assisted nucleophilic attack of a deacylating water molecule on the ester carbonyl carbon of the intermediate resulting in tetrahedral intermediate-2 (Figure 8). In contrast to the general base Glu166 of RTEM-1 (4.3 Å from Ser70), in glutaminases this function is expected to be performed by the conserved Tyr201 (4.8 Å from Ser74). The Tyr201 side chain oxygen accepts the proton from the deacylating water molecule and transfers it to the Ser74 O^γ, thereby regenerating the active site (Figure 8).

Physiological Role of Glutaminases

The main cellular function of glutaminases was proposed to be associated with the control of the intracellular pool of glutamine, which represents the central nitrogen metabolite in most organisms (17,55,56). Depending on the growth conditions the intracellular concentrations of glutamine in enterobacteria and *Bacillus* can vary in a wide range: from 0.02 to 27.0 mM (57–62). Therefore, the substrate affinities of both lower and higher affinity glutaminases from *E. coli* and *B. subtilis* fall within this range, and both forms can play a significant role in the intracellular glutamine metabolism. In *B. subtilis*, YbgJ was shown to be involved in the assimilation of glutamine, and the expression of its gene is activated by the GlnK-GlnL two-component system in response to glutamine (26). Moreover, increased resistance of enzymatic activity of the *E. coli* YbaS to low pH *in vitro* (Supporting Information Figure 1A) and elevated expression of its gene in response to acid shock *in vivo* (63) imply that this glutaminase might represent an additional component of the acid resistance system in *E. coli*. Our preliminary results with *E. coli* glutaminase deletion strains show that on M9 minimal medium with glutamine as a sole source of nitrogen and carbon the Δ *yneH* and Δ *ybaS*, Δ *yneH* double deletion strains grew two times slower than the wild-type or Δ *ybaS* strains (data not shown). In addition, both *E. coli* glutaminase deletion strains demonstrated a reduced growth rate during the exponential growth phase in M9 minimal medium with glucose (0.4%), glutamine (20 mM), and pH 4.5–5.0 (data not shown). These results suggest that *E. coli* glutaminases are involved in the assimilation of extracellular glutamine and might also contribute to acid resistance. Future work is required to further characterize the catalytic mechanism and role of glutaminases in microbial metabolism.

ACKNOWLEDGMENT

We thank all members of the Ontario Centre for Structural Proteomics at the University of Toronto and the Structural Biology Center at Argonne National Laboratory for help in conducting these experiments. James Watson (EBI) is thanked for the discussion of the glutaminase sequence motifs.

REFERENCES

1. Nandakumar R, Yoshimune K, Wakayama M, Moriguchi M. Microbial glutaminase: biochemistry, molecular approaches and applications in the food industry. *J. Mol. Catal. B: Enzym* 2003;23:87–100.
2. Massova I, Mobashery S. Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases. *Antimicrob. Agents Chemother* 1998;42:1–17. [PubMed: 9449253]
3. Ghuysen JM. Serine beta-lactamases and penicillin-binding proteins. *Annu. Rev. Microbiol* 1991;45:37–67. [PubMed: 1741619]
4. Fisher JF, Meroueh SO, Mobashery S. Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity. *Chem. Rev* 2005;105:395–424. [PubMed: 15700950]
5. Wilke MS, Lovering AL, Strynadka NC. Beta-lactam antibiotic resistance: a current structural perspective. *Curr. Opin. Microbiol* 2005;8:525–533. [PubMed: 16129657]

6. Strynadka NC, Adachi H, Jensen SE, Johns K, Sielecki A, Betzel C, Sutoh K, James MN. Molecular structure of the acyl-enzyme intermediate in beta-lactam hydrolysis at 1.7 Å resolution. *Nature* 1992;359:700–705. [PubMed: 1436034]
7. Gordon E, Mouz N, Duee E, Dideberg O. The crystal structure of the penicillin-binding protein 2x from *Streptococcus pneumoniae* and its acyl-enzyme form: implication in drug resistance. *J. Mol. Biol* 2000;299:477–485. [PubMed: 10860753]
8. Paetzel M, Danel F, de Castro L, Mosimann SC, Page MG, Strynadka NC. Crystal structure of the class D beta-lactamase OXA-10. *Nat. Struct. Biol* 2000;7:918–925. [PubMed: 11017203]
9. Ibuka AS, Ishii Y, Galleni M, Ishiguro M, Yamaguchi K, Frere JM, Matsuzawa H, Sakai H. Crystal structure of extended-spectrum beta-lactamase Toho-1: insights into the molecular mechanism for catalytic reaction and substrate specificity expansion. *Biochemistry* 2003;42:10634–10643. [PubMed: 12962487]
10. Nandakumar R, Wakayama M, Nagano Y, Kawamura T, Sakai K, Moriguchi M. Overexpression of salt-tolerant glutaminase from *Micrococcus luteus* K-3 in *Escherichia coli* and its purification. *Protein Expression Purif* 1999;15:155–161.
11. Huerta-Saquero A, Calderon J, Arreguin R, Calderon-Flores A, Duran S. Overexpression and purification of *Rhizobium etli* glutaminase A by recombinant and conventional procedures. *Protein Expression Purif* 2001;21:432–437.
12. Klein M, Kaltwasser H, Jahns T. Isolation of a novel, phosphate-activated glutaminase from *Bacillus pasteurii*. *FEMS Microbiol Lett* 2002;206:63–67. [PubMed: 11786258]
13. Moriguchi M, Sakai K, Tateyama R, Furuta Y, Wakayama M. Isolation and characterization of salt-tolerant glutaminases from marine *Micrococcus luteus* K-3. *J. Ferment. Bioeng* 1994;77:621–625.
14. Weingand-Ziade A, Gerber-Decombaz C, Affolter M. Functional characterization of a salt- and thermotolerant glutaminase from *Lactobacillus rhamnosus*. *Enzyme Microb. Technol* 2003;32:862–867.
15. Yoshimune K, Shirakihara Y, Shiratori A, Wakayama M, Chantawannakul P, Moriguchi M. Crystal structure of a major fragment of the salt-tolerant glutaminase from *Micrococcus luteus* K-3. *Biochem. Biophys. Res. Commun* 2006;346:1118–1124. [PubMed: 16793004]
16. Yano S, Kamemura A, Yoshimune K, Moriguchi M, Yama-moto S, Tachiki T, Wakayama M. Analysis of essential amino acid residues for catalytic activity of glutaminase from *Micrococcus luteus* K-3. *J. Biosci. Bioeng* 2006;102:362–364. [PubMed: 17116585]
17. Curthoys NP, Watford M. Regulation of glutaminase activity and glutamine metabolism. *Annu. Rev. Nutr* 1995;15:133–159. [PubMed: 8527215]
18. Aledo JC, Gomez-Fabre PM, Olalla L, Marquez J. Identification of two human glutaminase loci and tissue-specific expression of the two related genes. *Mamm. Genome* 2000;11:1107–1110. [PubMed: 11130979]
19. Kenny J, Bao Y, Hamm B, Taylor L, Toth A, Wagers B, Curthoys NP. Bacterial expression, purification, and characterization of rat kidney-type mitochondrial glutaminase. *Protein Expression Purif* 2003;31:140–148.
20. Perez-Gomez C, Campos-Sandoval JA, Alonso FJ, Segura JA, Manzanares E, Ruiz-Sanchez P, Gonzalez ME, Marquez J, Mates JM. Co-expression of glutaminase K and L isoenzymes in human tumour cells. *Biochem. J* 2005;386:535–542. [PubMed: 15496140]
21. Hartman SC. Glutaminase of *Escherichia coli* I. Purification and general catalytic properties. *J. Biol. Chem* 1968;243:853–863. [PubMed: 4966660]
22. Prusiner S, Davis JN, Stadtman ER. Regulation of glutaminase B in *Escherichia coli* I. Purification, properties, and cold lability. *J. Biol. Chem* 1976;251:3447–3456. [PubMed: 6454]
23. Prusiner S, Miller RE, Valentine RC. Adenosine 3':5'-cyclic monophosphate control of the enzymes of glutamine metabolism in *Escherichia coli*. *Proc. Natl. Acad. Sci. U.S.A* 1972;69:2922–2926. [PubMed: 4404145]
24. Prusiner S. Regulation of glutaminase levels in *Escherichia coli*. *J. Bacteriol* 1975;123:992–999. [PubMed: 239927]
25. Neidhardt, FC.; Curtiss, R. *Escherichia coli* and *Salmonella*: cellular and molecular biology. Vol. 2nd ed.. Washington, DC: ASM Press; 1996. p. 2

26. Satomura T, Shimura D, Asai K, Sadaie Y, Hirooka K, Fujita Y. Enhancement of glutamine utilization in *Bacillus subtilis* through the GlnK-GlnL two-component regulatory system. *J. Bacteriol* 2005;187:4813–4821. [PubMed: 15995196]
27. Zhang RG, Skarina T, Katz JE, Beasley S, Khachatryan A, Vyas S, Arrowsmith CH, Clarke S, Edwards A, Joachimiak A, Savchenko A. Structure of *Thermotoga maritima* stationary phase survival protein SurE: a novel acid phosphatase. *Structure* 2001;9:1095–1106. [PubMed: 11709173]
28. Gonzalez CF, Proudfoot M, Brown G, Korniyenko Y, Mori H, Savchenko AV, Yakunin AF. Molecular basis of formaldehyde detoxification. Characterization of two S-formyl-glutathione hydrolases from *Escherichia coli*, FrmB and YeiG. *J. Biol. Chem* 2006;281:14514–14522. [PubMed: 16567800]
29. Bergmeyer HU. Enzymatic analysis of the new generation. *Fresenius' Z. Anal. Chem* 1984;319:883–889.
30. Neeley WE, Phillipson J. Automated enzymatic method for determining ammonia in plasma, with 14-day reagent stability. *Clin. Chem* 1988;34:1868–1869. [PubMed: 3416435]
31. Heering HA, Weiner JH, Armstrong FA. Direct detection and measurement of electron relays in a multicentered enzyme: Voltammetry of electrode-surface films of *E. coli* fumarate reductase, an iron-sulfur flavoprotein. *J. Am. Chem. Soc* 1997;119:11628–11638.
32. Galarneau A, Primeau M, Trudeau LE, Michnick SW. Beta-lactamase protein fragment complementation assays as in vivo and in vitro sensors of protein protein interactions. *Nat. Biotechnol* 2002;20:619–622. [PubMed: 12042868]
33. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, Datsenko KA, Tomita M, Wanner BL, Mori H. Construction of *Escherichia coli* K-12 in-frame, single-gene knockout mutants: the Keio collection. *Mol. Syst. Biol* 2006;2:1–11.
34. Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc. Natl. Acad. Sci. U.S.A* 2000;97:6640–6645. [PubMed: 10829079]
35. Silhavy, TJ.; Berman, ML.; Enquist, LW. Experiments with gene fusions. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1984. p. 15
36. Tucker DL, Tucker N, Conway T. Gene expression profiling of the pH response in *Escherichia coli*. *J. Bacteriol* 2002;184:6551–6558. [PubMed: 12426343]
37. Kimber MS, Vallee F, Houston S, Necakov A, Skarina T, Evdokimova E, Beasley S, Christendat D, Savchenko A, Arrowsmith CH, Vedadi M, Gerstein M, Edwards AM. Data mining crystallization databases: knowledge-based approaches to optimize protein crystal screens. *Proteins* 2003;51:562–568. [PubMed: 12784215]
38. Rosenbaum G, Alkire RW, Evans G, Rotella FJ, Lazarski K, Zhang RG, Ginell SL, Duke N, Naday I, Lazarz J, Molitsky MJ, Keefe L, Gonczy J, Rock L, Sanishvili R, Walsh MA, Westbrook E, Joachimiak A. The Structural Biology Center 19ID undulator beamline: facility specifications and protein crystallographic results. *J. Synchrotron Radiat* 2006;13:30–45. [PubMed: 16371706]
39. Segraves EN, Chruszcz M, Neidig ML, Ruddat V, Zhou J, Weckler AT, Minor W, Solomon EI, Holman TR. Kinetic, spectroscopic, and structural investigations of the soybean lipoxygenase-1 first-coordination sphere mutant, Asn694Gly. *Biochemistry* 2006;45:10233–10242. [PubMed: 16922498]
40. Naaza J. AMoRe: an automated package for molecular replacement. *Acta Crystallogr* 1994;A50:157–163.
41. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. *Acta Crystallogr., Sect. D: Biol. Crystallogr* 2004;60:2126–2132. [PubMed: 15572765]
42. Jones TA, Zou J-Y, Cohen SW, Kjeldgaard M. Improved methods for the building of protein models in electron density maps and the location of errors in these models. *Acta Crystallogr. A* 1991;47:110–119. [PubMed: 2025413]
43. Winn M, Isupov M, Murshudov GN. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. *Acta Crystallogr. D* 2001;57:122–133. [PubMed: 11134934]
44. Perrakis A, Morris R, Lamzin VS. Automated protein model building combined with iterative structure refinement. *Nat. Struct. Biol* 1999;6:458–463. [PubMed: 10331874]
45. Terwillinger T. SOLVE and RESOLVE: automated structure solution and density modification. *Methods Enzymol* 2003;374:22–37. [PubMed: 14696367]

46. The CCP4 suite: programs for protein crystallography. *Acta Crystallogr., Sect. D: Biol. Crystallogr* 1994;50:760–763. [PubMed: 15299374]
47. Prusiner S, Stadtman ER. Regulation of glutaminase B in *Escherichia coli* III. Control by nucleotides and divalent cations. *J. Biol. Chem* 1976;251:3463–3469. [PubMed: 776970]
48. Roberts J, Holcenberg JS, Dolowy WC. Isolation, crystallization, and properties of *Achromobacteraceae* glutaminase-asparaginase with antitumor activity. *J. Biol. Chem* 1972;247:84–90. [PubMed: 5017769]
49. Holcenberg JS, Ericsson L, Roberts J. Amino acid sequence of the diazooxonorleucine binding site of *Acinetobacter* and *Pseudomonas* 7A glutaminase-asparaginase enzymes. *Biochemistry* 1978;17:411–417. [PubMed: 619999]
50. Ortlund E, Lacount MW, Lewinski K, Lebiada L. Reactions of *Pseudomonas* 7A glutaminase-asparaginase with diazo analogues of glutamine and asparagine result in unexpected covalent inhibitions and suggests an unusual catalytic triad Thr-Tyr-Glu. *Biochemistry* 2000;39:1199–1204. [PubMed: 10684596]
51. Aghaiypour K, Wlodawer A, Lubkowski J. Do bacterial l-asparaginases utilize a catalytic triad Thr-Tyr-Glu? *Biochim Biophys. Acta* 2001;1550:117–128. [PubMed: 11755201]
52. Bebrone C, Moali C, Mahy F, Rival S, Docquier JD, Rossolini GM, Fastrez J, Pratt RF, Frere JM, Galleni M. CENTA as a chromogenic substrate for studying beta-lactamases. *Antimicrob. Agents Chemother* 2001;45:1868–1871. [PubMed: 11353639]
53. Holm L, Sander C. Protein structure comparison by alignment of distance matrices. *J. Mol. Biol* 1993;233:123–138. [PubMed: 8377180]
54. Lobkovsky E, Moews PC, Liu H, Zhao H, Frere JM, Knox JR. Evolution of an enzyme activity: crystal-lographic structure at 2-Å resolution of cephalosporinase from the ampC gene of *Enterobacter cloacae* P99 and comparison with a class A penicillinase. *Proc. Natl. Acad. Sci. U.S.A* 1993;90:11257–11261. [PubMed: 8248237]
55. Medina MA. Glutamine and cancer. *J. Nutr* 2001;131:2539S–2542S. [PubMed: 11533309] (discussion 2550S–2551S)
56. Prusiner, SB.; Stadtman, ER. The enzymes of glutamine metabolism. New York: Academic Press; 1973.
57. Schutt H, Holzer H. Biological function of the ammonia-induced inactivation of glutamine synthetase in *Escherichia coli*. *Eur. J. Biochem* 1972;26:68–72. [PubMed: 4402918]
58. Fisher SH, Sonenshein AL. *Bacillus subtilis* glutamine synthetase mutants pleiotropically altered in glucose catabolite repression. *J. Bacteriol* 1984;157:612–621. [PubMed: 6141156]
59. Osorio AV, Camarena L, Salazar G, Noll-Louzada M, Bastarrachea F. Nitrogen regulation in an *Escherichia coli* strain with a temperature sensitive glutamyl-tRNA synthetase. *Mol. Gen. Genet* 1993;239:400–408. [PubMed: 7686246]
60. Ikeda TP, Shauger AE, Kustu S. *Salmonella typhimurium* apparently perceives external nitrogen limitation as internal glutamine limitation. *J. Mol. Biol* 1996;259:589–607. [PubMed: 8683567]
61. Hu P, Leighton T, Ishkhanova G, Kustu S. Sensing of nitrogen limitation by *Bacillus subtilis*: comparison to enteric bacteria. *J. Bacteriol* 1999;181:5042–5050. [PubMed: 10438777]
62. Javelle A, Severi E, Thornton J, Merrick M. Ammonium sensing in *Escherichia coli*. Role of the ammonium transporter AmtB and AmtB-GlnK complex formation. *J. Biol. Chem* 2004;279:8530–8538. [PubMed: 14668330]
63. Tucker DL, Tucker N, Ma Z, Foster JW, Miranda RL, Cohen PS, Conway T. Genes of the GadX-GadW regulon in *Escherichia coli*. *J. Bacteriol* 2003;185:3190–3201. [PubMed: 12730179]
64. Shindyalov IN, Bourne PE. Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. *Protein Eng* 1998;11:739–747. [PubMed: 9796821]




Figure 1. Structure-based sequence alignment of β -lactamase-like glutaminases from several bacteria and humans. The secondary structure elements are shown above (YbaS) and below (YbgJ) the alignment. Highly conserved residues are shaded and boxed. Residues comprising the β -lactamase signature motifs I, II, and III are marked by asterisks. The compared glutaminases are *E. coli* YbaS (P77454), *E. coli* YneH (P0A6W0), *M. luteus* GlsA (Q4U1A6), *H. sapiens* GlsK (O94925), *H. sapiens* GlsL (Q9UI32), *R. etli* GlsA (O87405), *B. subtilis* YlaM (O07637), and *B. subtilis* YbgJ (O31465).




Figure 2.

Crystal structures of glutaminases. Overall structure of the tetramers: YbaS (A) and YbgJ (B). Protein subunits are shown in different colors. Subunit structures of YbaS (C) and YbgJ (D) showing potential active sites. The secondary structure elements are shown in different colors (α -helices, cyan; β -strands, magenta; loops, salmon) and are numbered in the YbgJ structure (D). The potential active site is located in the area between $\alpha 3$, $\alpha 6$, and $\beta 8$, and the position of the catalytic Ser (Ser66 in YbaS and Ser74 in YbgJ) is indicated by the black arrow in the center of both structures.




Figure 3.

Close-up stereoview of the active sites of YbaS (A) and YbgJ with bound DON (B). The secondary structure elements are shown in different colors (α -helices, red; β -strands, yellow; loops, green). The side chains of the conserved catalytic residues and DON are shown as sticks (nitrogen atoms, blue; oxygens, red; the carbon atoms of DON, cyan). Note that YbgJ deamidates DON producing 5-oxo-L-norleucine (ON) covalently bound to the enzyme.




Figure 4.

Comparison of the active sites of glutaminases and β -lactamases. Stereoview of superpositions of the key catalytic residues in the active sites of YbgJ and (A) class A β -lactamase RTE-1 from *E. coli* (1fqg) or (B) class C β -lactamase AmpC from *E. cloacae* P99 (1xx2). The side chains of the YbgJ residues are shown in green, and the β -lactamase residues are shown in cyan. The numbers of the YbgJ residues are shown, whereas those in parentheses refer to the equivalent residues of the class A β -lactamase RTE-1 (A) or to the class C β -lactamase AmpC (B). There is no residue corresponding to Y253 in RTE-1 or to Y201 in AmpC. The superpositions were done on the whole proteins using the combinatorial extension method (64). The YbgJ/RTE-1 superposition had an rmsd of 3.5 Å, while the YbgJ/AmpC superposition had an rmsd of 3.3 Å.




Figure 5. Alanine replacement mutagenesis of YbaS: glutaminase activity of purified mutant proteins. The reaction mixtures contained 25 mM glutamine and 0.2 μg of YbaS, and the continuous assays were performed as described in Experimental Procedures.




Figure 6. Stereoview of the catalytic site of the YbgJ–DON complex. The omit map was generated by omitting both DON residues from the model and replacing both Ser74 residues by glycine. Green density represents the resulting $F_o - F_c$ map contoured at 2.3σ . This map is shown around the model of the YbgJ/DON complex (not showing bound water molecules); protein residues (white carbon atoms) around the covalently bound DON (cyan carbon atoms) of molecule A in the asymmetric unit are shown as a stick representation, and several residues in contact with DON are labeled.





Figure 7.
Proposed model of the binding of L-glutamine in the active site of YbgJ.

**Figure 8.**

Possible reaction mechanism of the hydrolysis of L-glutamine by glutaminases. The reaction proceeds through the following steps: (1) nucleophilic attack of the Ser74 oxygen to form the tetrahedral intermediate-1; (2) decomposition of the tetrahedral intermediate-1 with the production of the glutamyl-enzyme intermediate and ammonia; (3) nucleophilic attack of water and the formation of the tetrahedral intermediate-2; (4) release of the second product (glutamate) and formation of free enzyme.

Table 1

Kinetic Parameters of Glutaminases from *E. coli* (YbaS and YneH) and *B. subtilis* (YbgJ and YlaM) with Glutamine as a Variable Substrate

protein	K_m (mM)	V_{max} (units/mg) ^a	k_{cat} (s ⁻¹)	k_{cat}/K_m (M ⁻¹ s ⁻¹)
YbaS (wt) ^b	7.3 ± 0.3	153.5 ± 2.9	91.4 ± 1.7	12.5 × 10 ³
YneH (wt)	30.6 ± 2.7	169.7 ± 6.4	101.0 ± 3.8	3.4 × 10 ³
YlaM (wt)	7.6 ± 0.3	69.9 ± 1.1	38.8 ± 0.6	5.1 × 10 ³
YbgJ (wt)	27.6 ± 1.6	113.7 ± 3.2	67.7 ± 1.9	2.45 × 10 ³
YbaS (Q162A)	8.5 ± 0.4	134.3 ± 2.7	79.9 ± 1.6	9.4 × 10 ³
YbaS (G261A)	23.7 ± 1.7	83.9 ± 2.9	49.9 ± 1.7	2.1 × 10 ³
YbaS (wt + 1.5 mM Amp) ^c	10.7 ± 0.7	138.6 ± 4.9	82.5 ± 2.9	7.7 × 10 ³
YbaS (wt + 3.0 mM Amp)	12.3 ± 0.8	142.2 ± 4.7	84.6 ± 2.8	6.9 × 10 ³

^aUnits/mg = μmol min⁻¹ (mg of protein)⁻¹.

^bwt = wild type.

^cAmp = ampicillin.

Table 2
Crystallographic Data Collection and Model Refinement Statistics^a

	YbaS ^b tetragonal	YbaS (1u60)	YbgJ ^b (1mki)	YbgJ + DON (3brm)
Data Collection				
space group	<i>I</i> 4	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ 2 ₁ 2	<i>P</i> 2 ₁ 2 ₁ 2
cell dimensions				
<i>a</i> (Å)	239.8	50.5	71.3	71.2
<i>b</i> (Å)		155.9	81.5	184.7
<i>c</i> (Å)	50.1	164.2	51.5	51.4
wavelength	0.97948	0.97978	0.9793	0.9793
resolution (Å)	50–1.8 (1.86–1.8)	50–1.8 (1.86–1.8)	50–2.0 (2.07–2.0)	50–2.29 (2.38–2.29)
<i>R</i> _{sym} or <i>R</i> _{merge}	0.079 (0.388)	0.046 (0.153)	0.109 (0.502)	0.138 (0.521)
<i>I</i> / <i>σI</i>	27.7 (2.2)	25.6 (5.4)	5.4 (3.7)	5.2 (1.9)
completeness (%)	97.9 (83.4)	93.2 (75.2)	99.1 (98.5)	97.6 (83.8)
redundancy	6.8 (2.8)	3.9 (3.0)	10.2 (9.6)	6.3 (4.0)
Refinement				
resolution (Å)		40–1.80	40.7–2.0	34.5–2.29
no. of reflections		107720/5686	43940/4346	24770/1317
<i>R</i> _{work} / <i>R</i> _{free}		0.143/0.178	0.212/0.245	0.174/0.248
no. of atoms				
protein		9258	4844	4500
major ligand		75	16	20
solvent		1150	333	295
average <i>B</i> -factors				
overall		19.2	31.3	32.9
protein		17.2	30.9	32.3
waters		33.8	36.4	42.2
ligand/other ^c		39.9	42.6	42.4
Wilson <i>B</i> -factor		17.1	15.2	32.4
rms deviations				
bond lengths (Å)		0.015	0.006	0.018
bond angles (deg)		1.4	1.3	1.7
Ramachandran plot				
% in most favored regions		90.8	89.6	92.6
% in additionally allowed regions		8.0	8.9	6.5
% in disallowed regions		0.4	0.6	0.0

^aValues in parentheses are for the highest resolution shell.

^bData collection statistics are reported for data collection at the selenium peak wavelength; data were also collected for the inflection and remote wavelengths, but these are reported in the Supporting Information table.

^cIn the YbgJ + DON covalent complex, this refers to the average temperature factors for the ligand 5-oxo-L-norleucine. In the other glutaminase structures, there was no ligand, but molecules of 1,2-ethylene glycol and formate ions were found.